Table 5 Safety profile of rheumatoid arthritis treatment
Side effect | CHB group (n = 32) | Non-CHB group (n = 128) | p valuea |
|---|---|---|---|
Total side effects, n (%) | 15 (47) | 68 (53) | 0.572 |
Infections | 5 (16) | 16 (13) | 0.676 |
Gastrointestinal discomfort | 7 (22) | 22 (17) | 0.583 |
Trichomadesis | 2 (6) | 13 (10) | 0.547 |
Neutropenia | 2 (6) | 14 (11) | 0.484 |
Aminotransferase elevation | 6 (19) | 39 (30) | 0.244 |
  < two fold ULN | 4 (13) | 30 (23) | 0.234 |
  ≥ two fold, < three fold ULN | 1 (3) | 7 (6) | 0.630 |
  ≥ three fold ULN | 1 (3) | 2 (2) | 0.606 |
Antiviral prophylaxis | 14 (44) | 0 (0) | NA |
HBV reactivation | 11 (34) | 0 (0) | NA |
 Antiviral prophylaxis (+) | 3 (9) | 0 (0) | NA |
 Antiviral prophylaxis (−) | 8 (25) | 0 (0) | NA |